Serum Levels of Type III Procollagen Peptide in Diabetes Mellitus

Summary

Serum levels of type III procollagen peptide (P-III-P) were investigated in 19 patients with type 1 (insulin-dependent) and in 48 (25 orally treated, 23 insulinized) patients with type 2 (non insulin-dependent) diabetes mellitus. Among patients with type 2 diabetes, 16 orally treated and 14 insulin-treated subjects had macrovascular complications. P-III-P levels were not correlated with the duration of diabetes and with glucose control, nor were there any significant sex and age differences in the levels. P-III-P values were significantly higher in the sera of insulin-treated non insulin-dependent diabetic patients with macroangiopathy. These high values (18.5 ± 10.8 ng/ml) were in contrast with normal values in healthy subjects (8.5 ± 2.5, P < 0.001), insulin-dependent diabetics (9.9 ± 3.4 ng/ml, P < 0.01), non insulin-dependent diabetics treated with oral agents (8.2 ± 2.6 ng/ml, P < 0.001) and insulin-treated non insulin-dependent patients without macroangiopathy (8.2 ± 4.9 ng/ml, P < 0.001). Although this study does not demonstrate that an increase in type III collagen synthesis is responsible for the pathogenesis of macroangiopathy, it suggests that insulin-dependent fibroblast sensitization may play a role in the acceleration and progression of macroangiopathy.

Key-Words

Serum Type III Procollagen Peptide - Diabetes Mellitus - Insulin - Macroangiopathy